Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rameswari Chilamakuri

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Current Oncology (Toronto, Ont.)|September 22, 2022
Direct Targeting of the Raf-MEK-ERK Signaling Cascade Inhibits Neuroblastoma GrowthRameswari Chilamakuri, Saurabh Agarwal
Cells|January 26, 2021
COVID-19: Characteristics and TherapeuticsRameswari Chilamakuri, Saurabh Agarwal
Pharmaceuticals (Basel, Switzerland)|October 26, 2024
Repurposing of c-MET Inhibitor Tivantinib Inhibits Pediatric Neuroblastoma Cellular GrowthRameswari Chilamakuri, Saurabh Agarwal
Cancers|February 25, 2022
Dual Targeting of PI3K and HDAC by CUDC-907 Inhibits Pediatric Neuroblastoma GrowthRameswari Chilamakuri, Saurabh Agarwal
Biochimica Et Biophysica Acta. Reviews on Cancer|October 1, 2025
STAT3 axis in cancer and cancer stem cells: From oncogenesis to targeted therapiesDeepika Godugu, Rameswari Chilamakuri, Saurabh Agarwal
Pharmaceuticals (Basel, Switzerland)|October 29, 2025
Direct Targeting of CXCR2 Receptor Inhibits Neuroblastoma Growth: An In Vitro AssessmentRameswari Chilamakuri, Deepika Godugu, Saurabh Agarwal
Pharmaceuticals (Basel, Switzerland)|May 28, 2022
Inhibition of Polo-like Kinase 1 by HMN-214 Blocks Cell Cycle Progression and Inhibits Neuroblastoma GrowthRameswari Chilamakuri, Danielle Crystal Rouse, Saurabh Agarwal
Cancers|October 16, 2025
Striking at Survivin: YM-155 Inhibits High-Risk Neuroblastoma Growth and Enhances ChemosensitivityDanielle C Rouse, Rameswari Chilamakuri, Saurabh Agarwal
Translational Oncology|August 6, 2025
HJP 272, an endothelin receptor antagonist, and its role in cancer cell migration and invasionNabeela Baig, Rameswari Chilamakuri, Saurabh Agarwal, et al.
Life Sciences|July 31, 2022
Repurposing clofazimine for malignant pleural mesothelioma treatment - In-vitro assessment of efficacy and mechanism of actionVineela Parvathaneni, Rameswari Chilamakuri, Nishant S Kulkarni, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Current Oncology (Toronto, Ont.)|September 22, 2022
Direct Targeting of the Raf-MEK-ERK Signaling Cascade Inhibits Neuroblastoma GrowthRameswari Chilamakuri, Saurabh Agarwal
Cells|January 26, 2021
COVID-19: Characteristics and TherapeuticsRameswari Chilamakuri, Saurabh Agarwal
Pharmaceuticals (Basel, Switzerland)|October 26, 2024
Repurposing of c-MET Inhibitor Tivantinib Inhibits Pediatric Neuroblastoma Cellular GrowthRameswari Chilamakuri, Saurabh Agarwal
Cancers|February 25, 2022
Dual Targeting of PI3K and HDAC by CUDC-907 Inhibits Pediatric Neuroblastoma GrowthRameswari Chilamakuri, Saurabh Agarwal
Biochimica Et Biophysica Acta. Reviews on Cancer|October 1, 2025
STAT3 axis in cancer and cancer stem cells: From oncogenesis to targeted therapiesDeepika Godugu, Rameswari Chilamakuri, Saurabh Agarwal
Pharmaceuticals (Basel, Switzerland)|October 29, 2025
Direct Targeting of CXCR2 Receptor Inhibits Neuroblastoma Growth: An In Vitro AssessmentRameswari Chilamakuri, Deepika Godugu, Saurabh Agarwal
Pharmaceuticals (Basel, Switzerland)|May 28, 2022
Inhibition of Polo-like Kinase 1 by HMN-214 Blocks Cell Cycle Progression and Inhibits Neuroblastoma GrowthRameswari Chilamakuri, Danielle Crystal Rouse, Saurabh Agarwal
Cancers|October 16, 2025
Striking at Survivin: YM-155 Inhibits High-Risk Neuroblastoma Growth and Enhances ChemosensitivityDanielle C Rouse, Rameswari Chilamakuri, Saurabh Agarwal
Translational Oncology|August 6, 2025
HJP 272, an endothelin receptor antagonist, and its role in cancer cell migration and invasionNabeela Baig, Rameswari Chilamakuri, Saurabh Agarwal, et al.
Life Sciences|July 31, 2022
Repurposing clofazimine for malignant pleural mesothelioma treatment - In-vitro assessment of efficacy and mechanism of actionVineela Parvathaneni, Rameswari Chilamakuri, Nishant S Kulkarni, et al.
Pageof 2